4.5 Article

The Data from an Epidemiologic Study on the Insulin Resistance Syndrome Study:: The change and the rate of change of the age-blood pressure relationship

Journal

JOURNAL OF HYPERTENSION
Volume 26, Issue 10, Pages 1903-1911

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/HJH.0b013e32830b8937

Keywords

age; blood pressure; epidemiology

Funding

  1. INSERM
  2. CNAMTS
  3. Lilly
  4. Novartis Pharma
  5. Sanofi-Aventis
  6. Association Diabete Risque Vasculaire
  7. Federation Francaise de Cardiologie
  8. La Fondation de France
  9. ALFEDIAM
  10. ONIVINS
  11. Ardix Medical
  12. Bayer Diagnostics
  13. Becton Dickinson
  14. Cardionics
  15. Merck Sante
  16. Novo Nordisk
  17. Pierre Fabre
  18. Roche
  19. Topcon

Ask authors/readers for more resources

Objective Systolic blood pressure (SBP) and diastolic blood pressure (DBP) increase significantly until around 55 years, when SBP increases, DBP decreases. Whether the rates of change of SBP and DBP with age exhibit a similar dissociation has never been investigated. Design and participants The Data from an Epidemiologic Study on the Insulin Resistance Syndrome Study (D.E.S.I.R.), a 9-year longitudinal study included 2278 men and 2314 women, 30-65 years and SBP, DBP, and other cardiometabolic risk factors were determined every 3 years. Results Both SBP and DBP increased with age, more rapidly in women than in men. SBP and DBP were higher in the presence of risk factors (except smoking) but the increases with age were similar. For the rates of change, whereas Delta SBP increased linearly with age, Delta DBP declined as early as 45 years. This finding was not influenced by sex, menopause or other risk factors but was significantly attenuated in the presence of hypertension at baseline, whether treated or not, and mainly in men. Conclusion DBP increases with age between 30 and 60 years, Delta DBP tends to be markedly reduced as early as 45 years, in contrast with Delta SBP. Consequences for the understanding of vascular aging and antihypertensive therapy remain to be explored.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available